Related Experiment Video
Updated: Dec 7, 2025

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
Published on: September 14, 2010
Kawasaki Disease and Clinical Outcome Disparities Among Black Children
Luz A Padilla1, Jacqueline L Collins2, Adeniyi J Idigo1
1Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL.
Insights
Black children with Kawasaki disease experienced worse outcomes, including lower treatment response and more persistent coronary artery abnormalities. This highlights potential racial disparities in Kawasaki disease management and long-term health.
Area of Science:
- Pediatrics
- Cardiology
- Health Disparities
Background:
- Kawasaki disease is a leading cause of acquired heart disease in children.
- Understanding racial disparities in Kawasaki disease is crucial for equitable healthcare.
- Previous research has not fully elucidated differences in outcomes between Black and White children.
Purpose of the Study:
- To investigate racial disparities in Kawasaki disease prevalence.
- To assess differences in disease sequelae between Black and White children.
- To compare the effectiveness of intravenous gamma globulin (IVIG) treatment in Black versus White children.
Main Methods:
- Retrospective analysis of electronic medical records from 2000-2015.
- Inclusion of children diagnosed and treated for Kawasaki disease per American Heart Association criteria.
- Comparison of demographic, clinical, laboratory, and echocardiographic data between Black and White patients.
Main Results:
- Black children showed lower response rates to IVIG treatment within 10 days of fever onset (86.6% vs 95.6%).
- Black children experienced longer hospitalizations and required more ancillary treatments.
- A higher proportion of Black children had persistent coronary artery abnormalities at follow-up echocardiograms (21.2% vs 6.9% at third follow-up).
Conclusions:
- Black children with Kawasaki disease exhibit higher IVIG-refractory rates and more severe inflammatory markers.
- Despite similar initial treatment timing, Black children had a greater risk of persistent coronary artery abnormalities.
- Findings suggest significant racial disparities in Kawasaki disease outcomes, necessitating further investigation and targeted interventions.
Objective:
To determine whether Black children with Kawasaki disease exhibit disparities in prevalence, sequelae, and response to intravenous gamma globulin (IVIG) treatment.
Study Design:
International Classification of Diseases codes were used to identify children with Kawasaki disease admitted to a tertiary center in the southeastern US. Subjects diagnosed and treated according to American Heart Association criteria were included. Demographic, laboratory, clinical, and echocardiographic data from the electronic medical record (2000-2015) were compared between Blacks and Whites.
Results:
Data from 369 subjects (52% Whites and 48% Blacks) were included in our analysis. No significant differences related to timely admission, IVIG treatment, or coronary artery (CA) abnormalities during hospitalization were observed. Blacks showed lower IVIG response rates than Whites for patients administered IVIG within 10 days of fever onset (86.6% vs 95.6%; P = .007). Blacks received more ancillary drugs (9.6% vs 2.6%; P = .003), and endured longer hospitalizations (mean, 5 ± 3.9 days vs 3.4 ± 2.2 days; P = .001). Blacks presented with higher C-reactive protein level and erythrocyte sedimentation rate and lower hemoglobin, albumin, and sodium levels. Blacks had a higher proportion of persistent CA abnormalities than Whites at second follow-up echocardiogram (14.5% vs 6.3%; P = .03), and at third follow-up echocardiogram (21.2% vs 6.9%; P = .01).
Conclusions:
Compared with White children, Black children with Kawasaki disease had higher IVIG refractory prevalence, more severe inflammation, more ancillary treatments, and longer hospitalizations. Despite no racial differences in time to diagnosis or initial treatment, there was greater CA abnormality persistence among Black children at follow-up.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Chronic Kidney Disease II: Clinical Manifestations
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Bias in Epidemiological Studies

